August 28th 2024, 12:00pm
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
August 23rd 2024, 7:00pm
One expert explained why chronic lymphocytic leukemia is erroneously considered a ‘good cancer.’
From social work to cardio-oncology, there is a wide array of resources potentially available to patients, as one expert explained.
One expert explains why most of the time clinical trial enrollment is ‘the correct answer’ for patients.
There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon.
August 23rd 2024, 4:10pm
Experts discuss unmet needs and challenges faced by patients with uveal melanoma. This program was made possible with support from Immunocore.
August 23rd 2024, 4:05pm
Nathan L. Scott, M.D., discusses the safety and efficacy of tebentafusp. This program was made possible with support from Immunocore.
August 23rd 2024, 3:59pm
Nathan L. Scott, M.D., provides a brief overview of the current guidelines for treatment of metastatic uveal melanoma, as well as what considerations go into choosing the appropriate treatment for it. This program was made possible with support from Immunocore.
August 23rd 2024, 3:52pm
Nathan L. Scott, M.D., discusses the risk of recurrence within diagnosed uveal melanoma patients. Uveal Melanoma Prognosis and Risk Stratification
August 23rd 2024, 3:44pm
Nathan L. Scott, M.D., details what tests a patient should expect if they wish to confirm a uveal melanoma diagnosis. This program was made possible with support from Immunocore.
Trodelvy Plus Keytruda May Slow Progression in mTNBC
Pausing BTKi for Vaccine Did Not Boost Immunity in CLL
“Chillin’ Out” and Finding Our Cancer Community
Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes